Antagonists of p38 MAPK as therapeutics for acute lymphoblastic leukemia.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/512431

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

New therapies are needed to treat patients with leukemia. Moving leukemic cells into the blood reduces their growth and increases the effects of chemotherapy. Currently we cannot move leukemic cells into the blood without moving normal blood forming cells, making them more sensitive to chemotherapy. We have identified a drug that only affects leukemic cell movement. This study will examine the potential of this drug to treat leukemia.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $521,961.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

NOD-SCID mouse model | anti-cancer drugs | cancer and related disorders | cell death-apoptosis | haematological malignancy | leukaemia in adults | leukaemia in children | leukemia | pre-B acute lymphoblastic leukemia

Related Links